Philippe Bouissou, new Senior Development Director at Almirall

Barcelona, 29 May 2008.- Almirall announces the appointment of Philippe Bouissou as Senior Development Director reporting to the Executive Director of the R&D Area, Dr Per Olof Andersson. This appointment reinforces the development team and is a further example of Almirall’s commitment to expanding its R&D area.

Dr Bouissou brings to this position over 20 years’ experience in the pharmaceutical industry, having led global development projects from its very beginning to successful commercialisation of medicines in cardiovascular, infectious diseases, metabolic disorders and dermatology therapeutic areas.

Philippe Bouissou has a PhD in Biochemistry and Pharmacology from the University of Paris and a solid background in research and development. He worked as a researcher at UCLA (USA), INSERM and the University Paul Sabatier (France). Dr Bouissou has held various positions in R&D at Sandoz (France), Wyeth-Ayerst Research & Development (France), Pfizer Global Research and Development (UK), Pfizer Global Medical Affairs (USA) and Galderma R&D (France).

Almirall

Almirall, an international pharmaceutical company based on innovation and committed to health, headquartered in Barcelona, Spain, researches, develops, manufactures and commercialises its own R&D and licensed drugs with the aim of improving people’s health and wellbeing.

The therapeutic areas on which Almirall focuses its research resources are related to the treatment of asthma, COPD (Chronic Obstructive Pulmonary Disease), psoriasis, rheumatoid arthritis and multiple sclerosis.

Almirall is currently present in over 70 countries with direct presence in Europe and Latin America.

More information:

Ketchum/SEIS

Sonia San Segundo / Victoria Hernández

sonia.sansegundo@ketchum.com

victoria.hernandez@ketchum.com

Tel.: 91 788 32 00